Search

Your search keyword '"Lightbody, Elizabeth"' showing total 217 results

Search Constraints

Start Over You searched for: Author "Lightbody, Elizabeth" Remove constraint Author: "Lightbody, Elizabeth" Publication Year Range Last 50 years Remove constraint Publication Year Range: Last 50 years
217 results on '"Lightbody, Elizabeth"'

Search Results

1. Personalised progression prediction in patients with monoclonal gammopathy of undetermined significance or smouldering multiple myeloma (PANGEA): a retrospective, multicohort study

4. Prevalence of monoclonal gammopathies and clinical outcomes in a high-risk US population screened by mass spectrometry: a multicentre cohort study

5. Inhibition of MICA and MICB shedding enhances memory-like NK-cell–mediated cytotoxicity against multiple myeloma

6. Equipping Stroke Nurses to Take on Extended Roles Within Acute Stroke Care Through an Advanced Practice Fellowship: An Evaluation Study

8. Supplementary Figures and Tables from MinimuMM-seq: Genome Sequencing of Circulating Tumor Cells for Minimally Invasive Molecular Characterization of Multiple Myeloma Pathology

9. Data from MinimuMM-seq: Genome Sequencing of Circulating Tumor Cells for Minimally Invasive Molecular Characterization of Multiple Myeloma Pathology

10. OA-35 High-throughput plasma proteomics to define the precursor multiple myeloma proteome and identify candidate high-risk disease biomarkers of progression

11. P-097 Single-cell RNA sequencing of circulating tumor cells in precursor myeloma patients reveals early mechanisms of disease dissemination

12. P-411 Large-scale single-cell dissection of immune dysregulation in patients with monoclonal gammopathies

13. P-101 Single-cell RNA sequencing of 1.3 million plasma cells from patients with MGUS and SMM

14. Systematic characterization of therapeutic vulnerabilities in Multiple Myeloma with Amp1q reveals increased sensitivity to the combination of MCL1 and PI3K inhibitors

18. Abstract 796: Altered immune response to vaccination in patients with plasma cell premalignancy

22. Cancer cell genotype associated tumor immune microenvironment exhibits differential response to therapeutic STING pathway activation in high-grade serous ovarian cancer

23. MinimuMM-seq: Genome Sequencing of Circulating Tumor Cells for Minimally Invasive Molecular Characterization of Multiple Myeloma Pathology

24. Monitoring Plasma Cells and Clonal Emergence through Genome Sequencing of Circulating Tumor Cells for Minimally Invasive Molecular Characterization of Multiple Myeloma

25. Single-Cell RNA Sequencing of Rare Circulating Tumor Cells in Precursor Myeloma Patients Reveals Molecular Underpinnings of Tumor Cell Circulation

26. High-Throughput Plasma Proteomic Profiling to Identify Candidate High-Risk Disease Biomarkers in Precursor Multiple Myeloma Patients

27. Single-Cell RNA-Sequencing of 245 Tumor Samples from Patients with MGUS and Smoldering Multiple Myeloma Reveals Novel Insights into Malignant Plasma Cell Biology

28. Single-Cell RNA-Sequencing of 370 Bone Marrow and Peripheral Blood Immune Cell Samples from Patients with MGUS and Smoldering Multiple Myeloma Reveal Significant Immune Dysregulation at the MGUS Stage, and Novel Interactions between Tumor and Immune Cells

29. Dysregulated Humoral and Cellular Response to Sars-Cov-2 Vaccination in Patients with MGUS and SMM

31. Reconstructing the Genomic History of Multiple Myeloma Precursor Disease: Novel Insights and Clinical Applicability

32. Single-Cell RNA-Sequencing Identifies Immune Biomarkers of Progression in Patients with High-Risk Smoldering Multiple Myeloma Treated with Immunotherapy

33. Persistence of Monoclonal Gammopathies in Serial Samples from a US Population-Based Screening Study

34. Immune biomarkers of response to immunotherapy in patients with high-risk smoldering myeloma

35. P-055: Monitoring the emergence of multiple myeloma high-risk subclones with whole-genome sequencing of circulating tumor cells

36. OAB-036: The PANGEA model: dynamic modeling for personalized prediction of precursor disease progression to multiple myeloma

37. PTEN and BRCA1 tumor suppressor loss associated tumor immune microenvironment exhibits differential response to therapeutic STING pathway activation in a murine model of ovarian cancer

38. Abstract 3582: Single-cell RNA-sequencing for immune profiling of SARS-CoV2 vaccine response in healthy individuals and patients with precursor plasma cell malignancies

39. Abstract 5162: TuFEst: a sensitive and cost-effective pan-cancer detection approach with accurate tumor fraction estimation

40. Abstract 641: Single-cell RNA sequencing of rare circulating tumor cells in precursor myeloma patients reveals molecular underpinnings of tumor cell circulation

41. Abstract 640: Genome sequencing of circulating multiple myeloma cells for minimally invasive molecular characterization of precursor disease pathology

42. Abstract 5277: Humoral SARS-CoV-2 response in asymptomatic precursor plasma cell dyscrasia patients: IMPACT study results

43. Abstract 2259: Predictive modeling of smoldering multiple myeloma progression to multiple myeloma by continuous variable analysis

44. Mass cytometry staining for human bone marrow clinical samples

45. Attenuated response to SARS-CoV-2 vaccine in patients with asymptomatic precursor stages of multiple myeloma and Waldenstrom macroglobulinemia

47. Non-Invasive Liquid Biopsy to Quantify and Molecularly Characterize Circulating Multiple Myeloma Cells in the Assessment of Precursor Disease Pathology

48. High Prevalence of Monoclonal Gammopathy in a Population at Risk: The First Results of the Promise Study

49. Minimal Residual Disease in Myeloma: Application for Clinical Care and New Drug Registration

Catalog

Books, media, physical & digital resources